Role of Serotonin and Noradrenaline in the Rapid Antidepressant Action of Ketamine
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Depression is a chronic and debilitating illness that interferes severely with many human behaviors, and is the leading cause of disability in the world. There is data suggesting that deficits in serotonin neurotransmission can contribute to the development of depression. Indeed, >90% of prescribed antidepressant drugs act by increasing serotonergic transmission at the synapse. However, this increase is offset by a negative feedback operating at the level of the cell body of the serotonin neurons in the raphe nuclei. In the present work, we demonstrate: first, the intracortical infusion of ketamine induced an antidepressant-like effect in the forced swim test, comparable to that produced by systemic ketamine; second, systemic and intracortical ketamine increased serotonin and noradrenaline efflux in the prefrontal cortex, but not in the dorsal raphe nucleus; third, systemic and intracortical administration of ketamine increased the efflux of glutamate in the prefrontal cortex and dorsal raphe nucleus; fourth, systemic ketamine did not alter the functionality of 5-HT1A receptors in the dorsal raphe nucleus. Taken together, these findings suggest that the antidepressant-like effects of ketamine are caused by the stimulation of the prefrontal projection to the dorsal raphe nucleus and locus coeruleus caused by an elevated glutamate in the medial prefrontal cortex, which would stimulate release of serotonin and noradrenaline in the same area. The impact of both monoamines in the antidepressant response to ketamine seems to have different time frames.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another microdialysis study observed increases in extracellular serotonin and norepinephrine in the mPFC but not in the DRN of rats two hours following treatment with ketamine (25 mg/kg, i.p.) (López-Gil et al., 2019).”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as López-Gil et al., 2019
In the citing paper
“Reverse dialysis of ketamine (300 μM, 1 μL/min) into the mPFC over a span of two hours replicated the increases in norepinephrine, serotonin, and glutamate in the mPFC but also produced an increase in glutamate within the DRN.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as López-Gil et al., 2019
In the citing paper
“Extracellular glutamate was also increased in the mPFC and the DRN two hours post-ketamine.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as López-Gil et al., 2019
Citations
Cites
The Rat Brain in Stereotaxic Coordinates
(1982) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 51,963
The rat brain in stereotaxic coordinates
Palkovits, M. (1983) · Neuropeptides · doi:10.1016/0143-4179(83)90049-5 · Cited by 28,831
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Diagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380
Cryan, J. F., Valentino, R. J., & Lucki, I. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.008 · Cited by 1,119
Current advances and trends in the treatment of depression
Blier, P., & de Montigny, C. (1994) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(94)90315-8 · Cited by 1,113
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Lucki, I. (1997) · Behavioural Pharmacology · doi:10.1097/00008877-199711000-00010 · Cited by 802
Artigas, F., Romero, L., de Montigny, C., & Blier, P. (1996) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)10037-0 · Cited by 655
A prefrontal cortex–brainstem neuronal projection that controls response to behavioural challenge
Warden, M. R., Selimbeyoglu, A., Mirzabekov, J. J., Lo, M., Thompson, K. R., Kim, S.-Y., Adhikari, A., Tye, K. M., Frank, L. M., & Deisseroth, K. (2012) · Nature · doi:10.1038/nature11617 · Cited by 645
Antidepressant effect of optogenetic stimulation of the medial prefrontal cortex
Covington, H. E., Lobo, M. K., Maze, I., Vialou, V., Hyman, J. M., Zaman, S., LaPlant, Q., Mouzon, E., Ghose, S., Tamminga, C. A., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1731-10.2010 · Cited by 621
DiazGranados, N., Ibrahim, L. A., Brutsche, N. E., Ameli, R., Henter, I. D., Luckenbaugh, D. A., Machado-Vieira, R., & Zarate, C. A. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05327blu · Cited by 564
Autoregulation of Serotonin Neurons: Role in Antidepressant Drug Action
Piñeyro, G., & Blier, P. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01417-0 · Cited by 537
Singh, J. B., Fedgchin, M., Daly, E. J., De Boer, P., Cooper, K., Lim, P., Pinter, C., Murrough, J. W., Sanacora, G., Shelton, R. C., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16010037 · Cited by 525
5-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants
Richardson-Jones, J. W., Craige, C. P., Guiard, B. P., Stephen, A., Metzger, K. L., Kung, H. F., Gardier, A. M., Dranovsky, A., David, D. J., Beck, S. G., et al. (2010) · Neuron · doi:10.1016/j.neuron.2009.12.003 · Cited by 450
Loughlin, S. E., Foote, S. L., & Grzanna, R. (1986) · Neuroscience · doi:10.1016/0306-4522(86)90156-9 · Cited by 437
Koike, H., Iijima, M., & Chaki, S. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.05.035 · Cited by 346
Antidepressant-Like Effects of Medial Prefrontal Cortex Deep Brain Stimulation in Rats
Hamani, C., Diwan, M., Macedo, C. E., Brandão, M. L., Shumake, J., Gonzalez-Lima, F., Raymond, R., Lozano, A. M., Fletcher, P. J., & Nobrega, J. N. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.025 · Cited by 324
Pérez, V., Gilaberte, I., Faries, D., Alvarez, E., & Artigas, F. (1997) · The Lancet · doi:10.1016/s0140-6736(96)08007-5 · Cited by 300
Invernizzi, R., Belli, S., & Samanin, R. (1992) · Brain Research · doi:10.1016/0006-8993(92)90914-u · Cited by 274
Fuchikami, M., Thomas, A., Liu, R., Wohleb, E. S., Land, B. B., DiLeone, R. J., Aghajanian, G. K., & Duman, R. S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1414728112 · Cited by 265
Genetic variation in cortico-amygdala serotonin function and risk for stress-related disease
Holmes, A. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.03.006 · Cited by 264
Adell, A., & Artigas, F. (1991) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/bf00251121 · Cited by 222
Self-citationPharmacological approaches to the challenge of treatment-resistant depression
Ionescu, D. F., Rosenbaum, J. F., & Alpert, J. E. (2015) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2015.17.2/dionescu · Cited by 212
Selective Activation of Postsynaptic 5-HT1A Receptors Induces Rapid Antidepressant Response
Blier, P. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00242-4 · Cited by 184
Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism
Gigliucci, V., O’Dowd, G., Casey, S., Egan, D., Gibney, S., & Harkin, A. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3024-x · Cited by 177
Fukumoto, K., Iijima, M., & Chaki, S. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.233 · Cited by 174
How does pindolol improve antidepressant action?
Artigas, F., Celada, P., Laruelle, M., & Adell, A. (2001) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01682-5 · Cited by 174
Self-citationSerotonin receptors in depression: from A to B
Nautiyal, K. M., & Hen, R. (2017) · F1000Research · doi:10.12688/f1000research.9736.1 · Cited by 173
Akinfiresoye, L., & Tizabi, Y. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3153-2 · Cited by 149
Bortolozzi, A. A., Castañé, A., Semakova, J., Santana, N., Alvarado, G., Cortés, R., Ferrés‐Coy, A., Fernández, G., Carmona, M. C., Tóth, M., et al. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.92 · Cited by 144
Challis, C., Beck, S. G., & Berton, O. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00043 · Cited by 137
Pham, T. H., Mendez-David, I., Defaix, C., Guiard, B. P., Tritschler, L., David, D. J., & Gardier, A. M. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.05.010 · Cited by 136
Effect of fluoxetine on extracellular 5-hydroxytryptamine in rat brain. Role of 5-HT autoreceptors
Hervás, I., & Artigas, F. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00579-2 · Cited by 123
Can, A., Zanos, P., Moaddel, R., Kang, H. J., Dossou, K. S. S., Wainer, I. W., Cheer, J. F., Frost, D. O., Huang, X.-P., & Gould, T. D. (2016) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.235838 · Cited by 115
Amargós-Bosch, M., López-Gil, X., Artigas, F., & Adell, A. (2006) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005900 · Cited by 104
Self-citationGlutamatergic drive of the dorsal raphe nucleus
Soiza-Reilly, M., & Commons, K. G. (2011) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2011.04.004 · Cited by 94
Lorrain, D. S., Schaffhauser, H., Campbell, U. C., Baccei, C. S., Correa, L. D., Rowe, B. A., Rodriguez, D. E., Anderson, J. J., Varney, M. A., Pinkerton, A. B., et al. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300238 · Cited by 93
Geddes, S. D., Assadzada, S., Lemelin, D., Sokolovski, A., Bergeron, R., Haj-Dahmane, S., & Béïque, J.-C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522754113 · Cited by 90
Fukumoto, K., Iijima, M., Funakoshi, T., & Chaki, S. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx116 · Cited by 90
Nishitani, N., Nagayasu, K., Asaoka, N., Yamashiro, M., Shirakawa, H., Nakagawa, T., & Kaneko, S. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000649 · Cited by 87
Jiménez-Sánchez, L., Castañé, A., Pérez-Caballero, L., Grifoll, M., López-Gil, X., Campa, L., Galofré, M., Berrocoso, E., & Adell, A. (2016) · Cerebral Cortex · doi:10.1093/cercor/bhv133 · Cited by 83
Self-citationSałat, K., Siwek, A., Starowicz, G., Librowski, T., Nowak, G., Drabik, U., Gajdosz, R., & Popik, P. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.07.037 · Cited by 77
El Iskandrani, K. S., Oosterhof, C. A., El Mansari, M., & Blier, P. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115573809 · Cited by 75
Soiza-Reilly, M., Meye, F. J., Olusakin, J., Telley, L., Petit, E., Chen, X., Mameli, M., Jabaudon, D., Sze, J.-Y., & Gaspar, P. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0260-9 · Cited by 71
Amigó, J., Díaz, Á., Pilar-Cuéllar, F., Vidal, R., Martín, A., Compan, V., Pazos, Á., & Castro, E. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.08.037 · Cited by 68
Self-citationCatecholaminergic Strategies for the Treatment of Major Depression
Tremblay, P., & Blier, P. (2006) · Current Drug Targets · doi:10.2174/138945006775515464 · Cited by 65
Gasull-Camós, J., Tarrés-Gatius, M., Artigas, F., & Castañé, A. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.7 · Cited by 62
Tao, R., Ma, Z., & Auerbach, S. B. (1997) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701292 · Cited by 53
Hara, K., Yanagihara, N., Minami, K., Ueno, S., Toyohira, Y., Sata, T., Kawamura, M., Brüss, M., Bönisch, H., Shigematsu, A., et al. (1998) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/pl00005261 · Cited by 51
Gartside, S. E., Cole, A. J., Williams, A. P., McQuade, R., & Judge, S. J. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05577.x · Cited by 50
Kinoshita, H., Nishitani, N., Nagai, Y., Andoh, C., Asaoka, N., Kawai, H., Shibui, N., Nagayasu, K., Shirakawa, H., Nakagawa, T., et al. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy007 · Cited by 38
López-Gil, X., Jiménez-Sánchez, L., Romón, T., Campa, L., Artigas, F., & Adell, A. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001064 · Cited by 33
Self-citation
Cited by
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Brain NMDA Receptors in Schizophrenia and Depression
Adell, A. (2020) · Biomolecules · doi:10.3390/biom10060947 · Cited by 212
Self-citationMechanisms of ketamine and its metabolites as antidepressants
Hess, E. M., Riggs, L. M., Michaelides, M., & Gould, T. D. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114892 · Cited by 175
Yan, H., Wang, Y., Huo, F., & Yin, C. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c13223 · Cited by 142
Ketamine: Mechanisms and Relevance to Treatment of Depression
Kim, J., Suzuki, K., Kavalali, E. T., & Monteggia, L. M. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-051322-120608 · Cited by 147
Metadata
- Authors
- López-Gil, X., Jiménez-Sánchez, L., Campa, L., Castro, E., Frago, C., & Adell, A.
- Affiliations
- Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) , , ,
- Instituto de Investigaciones Biomédicas de Barcelona, CSIC, IDIBAPS , , ,
- Consejo Superior de Investigaciones Científicas (ES)
- Universidad de Cantabria (ES)
- Corresponding author
- Adell, Albert
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2019-06-05
- Volume
- 10
- Issue
- 7
- Pages
- 3318-3326
- ISSN
- 1948-7193 (ISSN-L)
- OpenAlex
- W2948831208
- Cited by
- 80
- References
- 57
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 11 · 2023: 13 · 2022: 12 · 2021: 12 · 2020: 9
- FWCI
- 5.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- ACS Chemical Neuroscience (publishedVersion, other-oa)
- PubMed (publishedVersion)
- UCrea (University of Cantabria) (publishedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by)
- Funders
- European Regional Development Fund
- Centro de Investigación Biomédica en Red de Salud Mental
- Instituto de Salud Carlos III (PI13/00038, PI16/00217)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, serotonin, norepinephrine, depression, prefrontal cortex, dorsal raphe nucleus, locus coeruleus, glutamate, serotonin efflux, noradrenaline efflux, 5-HT1A receptor, forced swim test, monoamines
- MeSH terms
- Animals, Antidepressive Agents, Depression, Ketamine, Male, Motor Activity, Norepinephrine, Serotonin, Rats, Wistar, Prefrontal Cortex, Glutamic Acid, Receptor, Serotonin, 5-HT1A, Rats, Serotonergic Neurons, Dorsal Raphe Nucleus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.